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1122 The Journal of Thoracic and CardObjective: Pulsatile left ventricular assist devices serving as mechanical circulatory
support for patients with end-stage heart failure are associated with complications,
including bleeding, thromboembolism, and infection. Axial-flow pumps might over-
come some of these shortcomings. Here we report our experience with long-term
application of the DeBakey VAD (MicroMed Technology, Inc, Houston, Tex).
Methods: Nine male transplant candidates (37  14 years) with severe hemody-
namic compromise (cardiac index, 1.6  0.5 L · min1 · m2; pulmonary capillary
wedge pressure, 27  6 mm Hg) and beginning end-organ failure despite inotropic
and intra-aortic balloon pump support received the DeBakey VAD. Clinical out-
come was evaluated.
Results: Cumulative support was 7.8 years, and the mean duration of support was
314 75 days (range, 229-438 days). Eight patients were transplanted, and one died
from intracerebral bleeding. Peripheral circulation and end-organ function recov-
ered rapidly after implantation. Continuous flow was able to maintain adequate
organ perfusion over the long term. Eight patients were discharged during support,
with good quality of life. There were no early bleedings, but there were late
bleedings in 3 patients caused by excessive anticoagulation and platelet inhibition.
Neurologic events occurred in 4 patients. Three patients recovered completely from
symptoms, and one had lethal intracerebral bleeding. Because of thrombus forma-
tion, the device was exchanged in 4 patients. With increasing experience, throm-
bolysis was performed in similar situations. All such patients underwent successful
transplantation. Hemolysis occurred, with events indicating thrombus formation.
Device-related infection was found in one patient.
Conclusions: The DeBakey VAD demonstrated its potential for long-term bridge to
transplantation. The risk for thrombus formation needs to be addressed by improve-
ment of pump technology and new strategies for platelet inhibition.
Since its introduction into the clinical arena, heart transplantation has beenlimited by a shortage of suitable donor hearts. Because of the resultingwaiting time for transplantation, many patients deteriorated and died on the
waiting list. Mechanical circulatory support provided those patients with an oppor-
tunity to survive until transplantation. After the first successful bridge to transplan-
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Ptation in 1969, remarkable improvements in technology
were achieved that made mechanical circulatory support
devices available for routine clinical use.1,2 Pulsatile left
ventricular assist devices (LVADs) became the standard for
bridging patients to heart transplantation. Their application
in critically ill transplant candidates reduced mortality on
the waiting list.3 However, pulsatile LVADs exhibit a num-
ber of disadvantages. Their big size requires large pump
pockets that increase the risk for bleeding and infection and
make them unsuitable for small patients. The pulsatile
mechanism creates uncomfortable noise, and despite anti-
coagulation and platelet inhibition, the inner surfaces and
prosthetic valves might be the origin of thrombosis and
embolism.4,5 In the intention to eliminate some of these
drawbacks, a new generation of blood pumps was devel-
oped. Nonpulsatile axial-flow pumps make little noise and,
because of their small size, cause less bleeding and infec-
tion. The MicroMed DeBakey VAD (MicroMed Technol-
ogy, Inc, Houston, Tex) was the first to be used in patients.6
The details of the pump have been described elsewhere.7 It
was evaluated in a multi-institutional trial in which our
center participated. Here we report our experience with
long-term support using this new technology.
Patients and Methods
Patient Selection and Patient Characteristics
Patients were selected according to a multicenter clinical trial. To
qualify for the study, the patients must have been listed for
transplantation and have demonstrated profound cardiac failure,
confirmed either by means of hemodynamics (pulmonary capillary
wedge pressure of 18 mm Hg, with either a cardiac index of
2.0 L · min1 · m2 or a systolic blood pressure of90 mm Hg)
or the need for extraordinary inotropic support (2 cat-
echolamines) or an intra-aortic balloon pump. Exclusion criteria
resembled those excluding a patient from cardiac transplantation.
For patients who our center considered suitable candidates for the
study despite existing exclusion criteria, such as young age or
increased creatinine or bilirubin levels, a special authorization was
TABLE 1. Patient characteristics
Patient
Age
(y) Sex
Body surface
area Diagnosis
NYHA
class
Cardiac
index
1 40 Male 1.71 DCM IV 2.2
2 27 Male 1.81 DCM IV 0.6
3 17 Male 1.68 DCM IV 1.8
4 27 Male 1.86 DCM IV 1.2
5 41 Male 2.06 ICM IV 2.0
6 51 Male 1.90 Acute MI IV 2.0
7 58 Male 2.07 ICM IV 1.9
8 20 Male 2.07 DCM IV 1.5
9 55 Male 1.85 ICM IV 2.0
NYHA, New York Heart Association; PCWP, pulmonary capillary wedge p
ischemic cardiomyopathy; MI, myocardial infarction.obtained by MicroMed. The study was approved by the local
The Journal of Thoracicinstitutional review board. Informed consent was obtained from
the patients, their relatives, or both, depending on the patient’s
clinical condition. Over a period of 15 months, 22 patients quali-
fying for the study underwent implantation of the original un-
coated DeBakey VAD. Nine (37  14 years) of the 22 patients
were supported for more than 200 days and are presented here.
This support time was chosen because the waiting time for elective
heart transplantation at our center frequently exceeds 200 days and
extends up to 15 months. In addition, it might help assess the
potential role of the pump for destination therapy. Patient charac-
teristics are displayed in Table 1. Hemodynamics were profoundly
compromised despite support with inotropics and the intra-aortic
balloon pump (cardiac index, 1.6  0.5 L · min1 · m2; pulmo-
nary capillary wedge pressure, 27  6 mm Hg; systolic blood
pressure, 80  8 mm Hg). All but 2 patients had beginning
end-organ failure involving the kidney, liver, or both.
Surgical Procedure
After a median sternotomy, a small abdominal wall pocket was
formed underneath the rectus muscle. After standard cannulation
of the ascending aorta and right atrium and initiation of cardio-
pulmonary bypass, the pump was implanted with the heart beating,
as we have already described for Novacor LVADs.8 The inflow
cannula was inserted into the left ventricular apex and oriented in
parallel to the interventricular septum. The pump was positioned
into the abdominal pocket, and the percutaneous cable was tun-
neled subcutaneously to exit on the contralateral side. The outflow
graft was anastomosed to the ascending aorta. After deairing, the
pump speed was gradually adjusted to provide sufficient pump
flow, and administration of nitric oxide supported right heart
function. Then cardiopulmonary bypass was stopped. The chest
was closed in standard fashion.
Postoperative Management
In the early postoperative period, it was important to adjust pump
speed, preload, and afterload to avoid suction and provide a pump
index of 2.0 L · min1 · m2 or greater. Later, pump speed usually
remained in each individual at the same level, which varied be-
tween patients from 8500 to 10,500 rpm. Positive fluid balance
Catecholamines IABP Intubation
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Liver
dysfunction
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Yes No No Yes No
Yes Yes No Yes No
Yes No No No No
Yes No No Yes Yes
Yes Yes Yes Yes No
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CSPAnticoagulation and inhibition of platelet aggregation were
adopted initially from our experience with pulsatile LVADs.9
Intravenous heparin at an activated partial thromboplastin time of
60 to 80 seconds was started on the first postoperative day (POD)
and, after clinical stabilization, was switched to oral phenprocou-
mon (international normalized ratio, 2.5-3.5). Inhibition of platelet
aggregation was started after removal of chest tubes, applying 300
mg of aspirin and 75 mg of dipyridamole daily. Specific monitor-
ing of platelet inhibition was not available. After our initial expe-
rience with recurrent events indicating thrombus formation, anti-
coagulation was intensified, aiming at an activated partial
thromboplastin time of 80 to 100 seconds during heparin therapy
and an international normalized ratio of 3.5 to 4.5 after switching
to phenprocoumon. For platelet inhibition, 75 mg of clopidogrel
was administered in addition to 300 mg of aspirin and 75 mg of
dipyridamol. The intensification of anticoagulation and platelet
inhibition was applied in patients 6 to 9. One patient (patient 9) had
heparin-induced thrombocytopenia for which anticoagulation was
switched to danaparoid (Orgaran; target blood level, 0.3-0.6
U/mL). For thrombolysis, recombinant tissue plasminogen activa-
tor was used. After an initial intravenous bolus of 50 mg, a second
intravenous dose of 50 mg was administered over a period of 2
hours.10
Results
Clinical Outcome
Operation time averaged 150  21 minutes, and cardiopul-
monary bypass time averaged 62  4 minutes. Cumulative
time of support was 7.8 years, and mean duration was 314
 75 days (range, 229-438 days). Three patients were
supported for more than 300 days, and 2 of those were
supported for more than 400 days. Eight patients underwent
transplantation, and one patient died from intracranial
bleeding (Table 2). Six patients (patients 2-4 and 6-8) spent
most of their time on support at home, and 2 patients
(patients 1 and 9) went home for weekends. Patient 5 was
ambulatory in the regular ward, but because of the rather
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Figure 1. Recovery of preoperatively compromised peripheral
organ perfusion, as indicated by lactate levels, after implantationTABLE 2. Clinical outcome and adverse events
Patient
Clinical
outcome
Duration of
support (d)
Pump
exchange
Pump 1
duration
(d)
Pump 2
duration
(d)
1 HTx 246 Yes 172 74
2 HTx 229 Yes 138 91
3 HTx 280 Yes 78 202
4 HTx 438 Yes 290 148
5 Death 253 No 253 –
6 HTx 299 No 299 –
7 HTx 412 No 412 –
8 HTx 274 No 274 –
9 HTx 399 No 399 –
HTx, Heart transplantation.complicated course, he was not discharged home.
ober 2005
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PHemodynamics
According to the pump and hemodynamic management
described above, pump flows from 3.5 to 7 L/min were
achieved, depending on the patient’s size and activity. This
allowed cessation of nitric oxide and inotropic therapy
within 24 to 48 hours after the operation, and in the later
course, it enabled the patients to perform normal daily
activities and exercise. Preoperatively compromised periph-
eral organ perfusion normalized rapidly (Figure 1). None of
the patients had right ventricular failure, which would have
required right ventricular assistance. Pulsatility was absent
in all patients in the initial postoperative period. Within the
first postoperative week, all patients regained pulsatility to a
variable extent. Echocardiography demonstrated closure of
the aortic valve at rest. In the later course, exercise caused
the aortic valve to open.
Bleeding
There were no intraoperative or early postoperative bleed-
ings. Later postoperatively, bleeding complications oc-
curred in 3 patients after intensive anticoagulation and
platelet inhibition were effective (Table 2). Patient 3 under-
went a pericardiocentesis with placement of a pericardial
tube for pericardial tamponade 11 days after device ex-
change. Five days later, a pericardial hematoma was re-
moved through resternotomy. Because of recurrent nose
bleeding, the patient received a temporary nasal tampon-
ade. In patient 5 a minithoracotomy was performed on
POD 15 for bleeding in the left pleural cavity. On POD
35, pericardial and pleural drains were placed for effu-
sion. In addition, the patient experienced recurrent epi-
sodes of nasopharyngeal bleeding that required several
otorhinolaryngeal interventions. In patient 6 a hematoma
of the device pocket was evacuated through resternotomy
on POD 13 and again on POD 17 for recurrence. All but
2 bleeding events occurred in patients 1 to 5 before the
anticoagulation and platelet inhibition protocol was
intensified.
Neurologic Events
Neurologic events occurred in 4 patients (Table 2). On POD
139, patient 4 experienced a transient episode of slurred
vision resolving within 2 hours, which correlated with a
small ischemic area in the left ventral thalamus on com-
puted tomography. On POD 397, he experienced a visual
field defect of the left lower quadrant on his left eye, which
disappeared completely. Computed tomography revealed an
ischemic zone in the area of the right posterior cerebral
artery. In patient 5 a minor subarachnoidal bleeding around
the left brainstem and left occipital lobe occurred on POD
157, which clinically correlated with diffuse headaches. On
POD 226, he again experienced headaches and transient
word-finding difficulties. Computed tomography showed
The Journal of Thoracicischemia of the left basal ganglia and a small anterior area
of the right medial cerebral artery, as well as a small
infarction with subsequent bleeding in the anterior region of
the left medial cerebral artery. On POD 249, he had massive
intracranial bleeding in the right hemisphere, which, despite
all medical and neurosurgical measures, finally caused the
patient’s death. Patient 6 complained of headaches on POD
250, correlating with a small ischemic infarction with sub-
sequent hemorrhage in the left occipital lobe. Four weeks
later, the bleeding was completely absorbed. On POD 50,
patient 9 experienced intracranial bleeding in the right pa-
rieto-occipital area, causing headaches and hemianopia to
the left. With resorption of the bleeding, the symptoms
disappeared. On POD 284, he experienced a left thalamus
infarction with subsequent right arm paresis. Clinical symp-
toms disappeared almost completely over time. On POD
355, he experienced bilateral amaurosis, corresponding with
a right thalamus infarction and an ischemic zone in the
posterior area of the left medial cerebral artery. Until trans-
plantation, cortical blindness improved gradually. In total,
patients 1 to 5 had 5 neurologic events. Under intensified
anticoagulation and platelet inhibition, patients 6 to 9 expe-
rienced 4 neurologic events. In one patient (patient 9) the
activity level was markedly reduced by neurologic symp-
toms (arm paresis and cortical blindness).
Pump Exchange and Thrombolysis
Because of suspected thrombus formation in the pump
causing flow decrease of less than 1 L/min with severe
compromise of hemodynamics, limiting activity level to bed
rest, the pump was exchanged in patient 1 on POD 172, in
patient 2 on POD 138, in patient 3 on POD 78, and in
patient 4 on POD 290 (Table 2). Thrombus formation was
found in the rear and front hub, around the bearing, and in
the inflow cannula. Operations went uneventfully, and later,
all patients underwent successful transplantation. With our
TABLE 3. Indices of hemolysis
Patient
PFH (mg/dL; normal, 0-8
mg/dL) LDH (U/L; normal, <240 U/L)
1 10.2  5.8 (3-31; 8) 685 318 (192-1514; 575)
2 9.6  5.4 (3-23; 7) 750 309 (144-1442; 748)
3 14.1  11.1 (4-61; 10) 940 458 (306-2134; 760)
4 8.8  4.1 (3-27; 8) 724 280 (342-1897; 654)
5 11.2  12.3 (2-77; 7) 648 347 (165-1957; 553)
6 22.9  28.0 (4-133; 11) 1396 1233 (127-6320; 917)
7 8.0  2.8 (3-16; 7) 430 140 (227-1152; 411)
8 5.7  2.1 (3-12; 6) 530 135 (257-896; 536)
9 19.0  32.7 (3-200; 9) 1132 596 (349-3640; 928)
Data are presented as means  SD (minimum-maximum; median) of the
complete duration of support. PFH, Plasma free hemoglobin; LDH, lactate
dehydrogenase.increasing experience, we performed recombinant tissue
and Cardiovascular Surgery ● Volume 130, Number 4 1125
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CSPplasminogen activator lysis when such situations occurred
(Table 2). In all cases normal pump function could be
restored. Thrombolysis was not associated with adverse
events. In patient 6 thrombolysis was applied on POD 296
and in patient 9 on POD 261. In patient 3 thrombolysis was
performed on days 29, 116, and 179 after the pump was
exchanged and in patient 4 on day 140 after pump exchange.
In total, patients 1 to 5 experienced 8 events requiring pump
exchange or thrombolysis, whereas in patients 6 to 9 only 2
such events occurred under intensified anticoagulation and
platelet inhibition.
Hemolysis
All patients showed laboratory signs of hemolysis, as indi-
cated by plasma free hemoglobin (PFH) and lactate dehy-
drogenase (LDH). In general, baseline levels of LDH were
continuously increased 2- to 3-fold above the normal range,
and PFH levels were between the upper normal limit and a
2-fold increase (Table 3). These increases of laboratory
parameters were not associated with clinical events. Simul-
taneous increases of LDH and PFH to greater than these
levels suggested thrombus formation associated with the
pump. Some of these incidents led to device malfunction
(Figure 2). There were some patients without any such
increases (Figure 2). Two patients (patients 6 and 9) had
jaundice after excessive increase of PFH (100 mg/dL) and
LDH (3000 U/L). In all other patients, increases of PFH
and LDH to greater than baseline values were not correlated
with clinical signs of hemolysis nor did they require blood
transfusion. Modification of the anticoagulation and platelet
inhibition protocol did not seem to have an effect on
device exchange
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On POD 105, patient 7 presented with secretion from the
driveline exit site and a small skin defect over the subcuta-
neous driveline channel. This resulted from mechanical
irritation after the patient had pursued his hobby of fishing
for several days. After antibiotic treatment, the secretion
stopped, and skin ulceration healed (Table 2).
Long-Term Organ Function
Kidney function recovered in patients who were in acute
renal failure preoperatively and stayed within normal limits
until the end of support (Figure 3, patient 2). In patients
without renal compromise at implantation, normal kidney
function was maintained until transplantation (Figure 3,
patient 3). After initial renal recovery, patient 5 experienced
renal dysfunction in the scenario of prolonged multiorgan
failure, despite sufficient pump flows of 4.5 to 7 L/min
(Figure 3, patient 5). Preoperatively compromised liver
function recovered within days after the operation and re-
mained normal until termination of support (Figure 4).
Discussion
Our experience with the DeBakey VAD indicates that it is
capable of providing adequate circulatory support in pa-
tients with severe heart failure. In the early postoperative
phase, the normalization of lactate, as well as kidney and
liver parameters demonstrates that the pump rapidly restores
normal peripheral circulation and end-organ perfusion, even
in patients with severely compromised preoperative hemo-
dynamics. In the long term, normal function of peripheral
organs is maintained for periods of more than 1 year.
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Ppracticed with patients receiving pulsatile LVADs.11 This
clinical experience contradicts the hypothesis that a pulsa-
tile blood pressure profile is necessary to keep adequate
peripheral perfusion in human subjects and confirms exper-
imental studies that demonstrated tolerance of nonpulsatile
blood flow in animals.12 However, true nonpulsatile flow
exists only in the initial phase. Within days, pulsatility
returns to a variable extent in all patients induced by the
recovering left ventricle, which transmits pulse waves
through the pump.13 This phenomenon might contribute to
the remarkable long-term tolerance of continuous flow. The
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Figure 3. Renal function during support with the DeBakey VAD,
as indicated by serum creatinine (day 0  implantation). Above
(patient 2): recovery of preoperative renal failure. Middle (patient
3): maintenance of normal renal function. Below (patient 5): after
initial renal recovery, progressive renal failure occurred in the
scenario of multiorgan failure.pump has also shown its capability for long-term support of
The Journal of Thoracicmore than 1 year and thereby qualifies as a device for bridge
to transplantation. Thus it can compete with pulsatile pumps
that demonstrated their long-term durability repeatedly.14,15
Moreover, because of the small size and the low noise, the
device provides good comfort and quality of life for the
patient. This is of particular advantage in long-term assis-
tance. One might argue that the required pump exchange in
4 patients indicates limited reliability and durability of the
DeBakey VAD. These events, however, are attributed to the
learning curve in our early patients. After it was realized
that anticoagulation and platelet inhibition needed to be
more intense than in patients with pulsatile devices and that
thrombus formation could be managed with thrombolysis,
all pumps were running for more than 250 days without the
need for exchange.10 The intensification of anticoagulation
and platelet inhibition resulted in a decrease of thrombotic
events associated with the pump. Similar experiences with
pump thrombus were made by other investigators who also
approached the problem with pump exchange, thromboly-
sis, or outflow graft ligation.16-18 Embolic events occurred
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Figure 4. Recovery of preoperatively compromised liver function,
as indicated by serum bilirubin, after implantation of the DeBakey
VAD ( day 0).in the late course after 100 days of support and were
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bances, and word-finding difficulties. Neurologic symp-
toms, such as arm paresis and cortical blindness, resulted in
a reduction of the patient’s activity level only in one patient.
This was in the patient with heparin-induced thrombocyto-
penia, which might have contributed to its cause. Other
ischemic occurrences, such as gastrointestinal ischemia,
which is known to occur in patients with pulsatile devices,
did not happen. In contrast to currently approved pulsatile
devices, the rate of thromboembolic events appeared to be
higher. In particular, the device cannot compete with the
low frequency of embolic episodes in pulsatile pumps with
textured inner surfaces (HeartMate), as seen in the RE-
MATCH trial.5,19-21 However, the severity and extent of
neurologic dysfunction was limited in most cases, perhaps
because of the small size of particles being ejected from the
pump.
There were no bleeding complications in the initial post-
operative period, which is attributed to the small size of the
pump requiring only limited dissection, little pump pockets,
and short operation times. Bleeding episodes, however,
occurred in the later course because of intense anticoagula-
tion and platelet inhibition. Although chest and nose bleeds,
as well as most intracranial bleeds, being small in size, did
not affect patient outcome unfavorably, a fatal intracranial
bleeding event caused the death of a patient, most likely
resulting from the intense anticoagulation and triple platelet
inhibition.
The bleeding events together with the thrombotic and
embolic episodes emphasize the most important and as yet
unsolved problem of how to manage anticoagulation and
platelet inhibition in patients on axial-flow pumps. Various
protocols were applied by using varying dosages of antico-
agulation and platelet inhibition,16-18 but none of those
approaches reduced thrombotic and bleeding events to a
satisfying extent. This might be explained, at least in part,
by the damage to blood cells, in particular platelets, by the
fast rotating impeller of the axial-flow pump, which has not
been seen to this extent in patients with pulsatile LVADs.22
Strategies are needed to reduce blood activation by such
impeller pumps and establish efficient therapy for platelet
inhibition. Specific monitoring of platelet inhibition seems
to be required to adjust antiplatelet therapy individually.
This was not feasible in our patients and might be consid-
ered a limitation of the study. However, the experience
obtained here prompted us to establish such methods for
guidance of antiaggregation therapy in future patients re-
ceiving mechanical circulatory support. In addition, im-
provement of pump technology and mechanics is needed to
reduce its thrombogenicity.
Injury of blood corpuscles by the pump also caused a
certain extent of hemolysis throughout the duration of sup-
port. Most of the time, this was clinically irrelevant. In-
1128 The Journal of Thoracic and Cardiovascular Surgery ● Octcreases in hemolysis indicated thrombus formation associ-
ated with the pump. Varying amounts of hemolysis were
also reported by other groups.16-18 Similar to our experi-
ence, they also found hemolysis to be correlated with throm-
bus formation.17 Thus reducing the incidence of thrombus
formation will also decrease the extent of hemolysis.
Although the series of patients is small, it seems that the
device is associated with a low incidence of infection.
Similar findings were described by other investigators of
patients with axial-flow pumps.16-18,23 This advantage be-
comes even more evident if one considers the long cumu-
lative support time of several years in our patients. More-
over, the reported infection might not have occurred without
provocation by means of mechanical irritation. The low rate
of infection appears to be due to the small size of the pump
resting motionless in the pocket and the flexibility of the
percutaneous cable.
In summary, the DeBakey VAD has been shown to
provide adequate circulatory support to bridge patients over
the long-term to heart transplantation. Compatibility of con-
tinuous blood flow with sufficient tissue perfusion and over-
all maintenance of life could be demonstrated. The new
dimension of patient comfort grants improved quality of
life. Its advantages are contrasted by thrombotic events
associated with the pump. New strategies in managing an-
ticoagulation and platelet inhibition and improvement of
pump technology are needed to overcome these shortcom-
ings.
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